Next Article in Journal
Experiences of Nurse Managers during the COVID-19 Outbreak in a Selected District Hospital in Limpopo Province, South Africa
Next Article in Special Issue
Cost-Effectiveness of Prostate Cancer Detection in Biopsy-Naïve Men: Ultrasound Shear Wave Elastography vs. Multiparametric Diagnostic Magnetic Resonance Imaging
Previous Article in Journal
Relationship between Prosocial Behaviours and Addiction Problems: A Systematic Review
Previous Article in Special Issue
The Role of Music Therapy for Children Undergoing Cancer Treatment in Singapore
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Healthcare
Volume 10
Issue 1
10.3390/healthcare10010075
healthcare-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis

by
Daniel Sur
1,2,*,
Cristina Lungulescu
3,†,
Irina-Ioana Puscariu
1,†,
Simona Ruxandra Volovat
4,†,
Madalina Preda
5,
Elena Adriana Mateianu
6 and
Cristian Virgil Lungulescu
7,*
1
Department of Medical Oncology, The Oncology Institute “Prof. Dr. Ion Chiricuţă”, 400015 Cluj-Napoca, Romania
2
Department of Medical Oncology, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400012 Cluj-Napoca, Romania
3
Doctoral School, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania
4
Department of Medical Oncology, University of Medicine and Pharmacy Grigore T Popa Iasi, 700115 Iasi, Romania
5
Department of Microbiology, Parasitology and Virology, Faculty of Midwives and Nursing, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
6
Institute of Oncology “Prof. Dr. Alexandru Trestioreanu”, Șoseaua Fundeni, 022238 Bucharest, Romania
7
Department of Medical Oncology, University of Medicine and Pharmacy Craiova, 200349 Craiova, Romania
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Healthcare 2022, 10(1), 75; https://doi.org/10.3390/healthcare10010075
Submission received: 15 November 2021 / Revised: 28 December 2021 / Accepted: 30 December 2021 / Published: 31 December 2021
(This article belongs to the Special Issue Cancer in Human Health and Healthcare)
Browse Figures
Review Reports Versions Notes

Abstract

:
Patients with microsatellite-instability-high (MSI-H) or mismatched repair-deficient colorectal cancer (CRC) appear to be responsive to checkpoint inhibitors. This study aimed to assess research trends in CRC immunotherapy. Publication patterns of articles covering immunotherapies in CRC in the Web of Science Core Collection database were retrospectively examined using VOS viewer software (version 1.6.16) prior to 25 May 2021. Ultimately, 3977 records were identified that were published between 1975 and 2021, which received a total of 128,681 citations (an average of 32.36 citations per item), with a noticeable rise in 2014. The majority of articles were published in the US (35.8%), China (17.7%), and Germany (9.4%). Publications mainly originated from the Institut National de la Santé Et De La Recherche Medicale Inserm, followed by the University of Texas System and Harvard University; however, Johns Hopkins University received the most citations (18,666 for 69 publications). The Journal of Clinical Oncology issued the most publications (n = 146), while the most referenced item (7724 citations) was published in the New England Journal of Medicine in 2012. The most common keywords were associated with tumors (expression and microsatellite instability) or immune system components (t-cells/dendritic cells). The findings demonstrate the scientific community’s interest in the MSI-H subtype of colorectal tumors and how immunotherapy may be employed more successfully to treat metastatic CRC.

1. Introduction

Colorectal cancer (CRC) is a common malignancy and one of the primary causes of cancer-related mortality today [1]. Early-stage CRC benefits from curative treatment consisting of either surgery (appropriate tumor resection and lymphadenectomy) or surgery coupled with adjuvant chemotherapy (combination of oxaliplatin and fluoropyrimidine). Metastatic CRC patients are rarely candidates for radical surgery. In such instances, the focus and methods of treatment shift to improve overall survival using chemotherapy, targeted agents, and more recently immunotherapy [2]. Among those breakthroughs, immunotherapy was one of the most promising. Rather than directly targeting cancer cells, immunotherapy helps the host immune system in combating the malignant process [3]. Following the effectiveness of immunotherapy in the treatment of melanoma and renal cell carcinoma, studies on different cancer types were conducted [4,5]. The results for CRC were largely underwhelming with the exception of a rare subtype-deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) tumors [6]. Currently, the field is considered promising, and research on the subject is ongoing.
Bibliometric’s purpose is to trace the research profiles of different countries, centers, and researchers by quantifying the aspects of the production and dissemination of the knowledge generated over a certain time period and, as a result, offering important analysis of scientific production, behavior, and development in research fields [7]. In many areas of medical studies, including cancer research, a broad range of bibliometric analyses has been employed [8].
This study aimed to evaluate the development and impact of immunotherapy-related articles in CRC. The intended outcome is to gain a better understanding of the current situation and trends of those research studies by analyzing their main characteristics.

2. Materials and Methods

This analysis was conducted on 25 May 2021 by using the Web of Science Core Collection database, which has wide coverage with professional article indexing for conducting searches [9]. Inclusion criteria were articles discussing immunotherapies in CRC, where an included article should mention any CRC and immunotherapy keywords in their title, abstract, or keywords, and it discusses CRC immunotherapies. The resulting articles were manually screened, and excluded articles were not related to CRC immunotherapies. Furthermore, corrections, retracted items, or news items were excluded from the analysis. It is worth mentioning that there were no limitations in the searched period and the language of articles.

2.1. Search Strategy

The keywords that were used to define CRC immunotherapies include “immunotherapy” OR “anti-CTLA-4” OR “anti-PD-1” OR “anti-PD-L1” OR “Ipilimumab” OR “Tremelimumab “OR “Nivolumab” OR “ Pembrolizumab” OR “ PDR001” OR “Atezolizumab” OR “Durvalumab” OR “ Avelumab”. Moreover, keywords such as “colorectal cancer” OR “cancer of the colon” OR “colorectal malignancy” OR “colorectal tumor” OR “colorectal neoplasm” OR “colon tumor” OR “colon neoplasm” were searched for colorectal cancer. In addition, the Web of Science “Topic” category was specified to be searched for articles containing the above-mentioned keywords in their title, abstract, author keywords, and Keywords Plus.
The quotation marks were employed to define the searched term, and the star “*” operator was utilized to search for a specific stem, regardless of the other part of the word. The resulting search query was as follows: TS = (“immunotherap*” OR “anti-CTLA-4” OR “anti-PD-1” OR “anti-PD-L1” OR “Ipilimumab” OR “Tremelimumab” OR “Nivolumab” OR “Pembrolizumab” OR “pda001” OR “Atezolizumab” OR “Durvalumab” OR “Avelumab”) AND TS = (“colorectal cancer” OR “cancer of the colon” OR “colorectal malignancy” OR “colorectal tumor” OR “colorectal neoplasm” OR “colon tumor” OR “colon neoplasm”).
The searched items were analyzed in the Web of Science platform and were also exported to be analyzed using VOS viewer software as detailed below.

2.2. Variables and Analysis

For the included articles, data were extracted regarding the following variables: open access articles, articles published each year, articles affiliated to countries and institutions, top journals publishing articles related to immunotherapy research related to CRC, and top 10 most cited articles related to immunotherapy research related to CRC. Regarding journals, their respective impact factor was extracted from the 2019 journal citation report. A citation report was also created for the included articles, where the total number of citations received and the average number of citations for each item were extracted.
VOS viewer (version 1.6.16) was employed for literature mapping in order to analyze the co-occurrence of keywords, citation, and co-authorship. Moreover, it calculates an indication of how strong an item is connected to the others (an indicator called “Total link strength”) [10]. For each conducted analysis, total documents, citations, and total link strength were reported.

3. Results

3.1. Web of Science Output

The initial query resulted in a total of 3995 articles. After refining our search and manually excluding non-related articles (Figure 1), a total of 3977 articles were included in our analysis. Furthermore, a total of 2096 (52.7%) were open access articles, and the included articles received a total of 128,681 citations, with an average of 32.36 citations per item.

3.1.1. Years

The first related article was published in 1975 [11], and since then, the number of articles has increased. Since 2014, the yearly number of articles published exceeded 100 articles. Figure 2 shows the number of articles during the last 10 years.

3.1.2. Countries and Institutions

Regarding countries, USA was the top country with 1423 (35.8%) publications, followed by China (n = 702; 17.7%) and Germany (n = 372; 9.4%). Figure 3 illustrates the top 10 countries regarding immunotherapy research related to CRC. The French-based Institut National De La Sante Et De La Recherche Medicale Inserm was the institution with the highest number of publications, with almost 144 (3.6%) publications, followed by the US-based University of Texas System (n = 140; 3.5%) and US-based Harvard University (n = 119; 3.0%). Table 1 details the top 10 institutions regarding immunotherapy research related to CRC.

3.1.3. Journals

The journals that published the highest number of papers were the Journal of Clinical Oncology (impact factor 32.96) with 146 publications, followed by Cancer Immunology Immunotherapy (impact factor 5.44) with 117 publications, and Oncoimmunology (Impact factor 5.87) with 95 publications. Table 2 tabulates the top 10 journals regarding the number of papers published related to immunotherapy in CRC according to the Web of Science database.

3.1.4. Top 10 Most Cited Articles

For the top 10 highest cited papers related to immunotherapy research and colorectal cancer, the top-cited paper was published in 2012 in the New England Journal of Medicine titled “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer”. Table 3 summarizes the top 10 highly cited papers related to immunotherapy in CRC according to the Web of Science database, all of which were open access articles.

3.2. VOS Viewer Analysis (Hotspots)

3.2.1. Keyword Analysis

Keywords provided by the authors of the paper and those that occurred more than 10 times in the WOS core database were enrolled in the final analysis. Of 11,065 keywords, 647 met the threshold and had the greatest total link strength. The keywords that appeared most were “immunotherapy” (1598 occurrences with a total link strength of 12,636) and “colorectal cancer” (1298 occurrences with a total link strength of 9429), and they were excluded from our keyword mapping as they were specifically searched for in the Web of Science database. The top resulting keywords were “expression” (541 occurrences with a total link strength of 4146), “microsatellite instability” (359 occurrences with a total link strength of 3141), and “dendritic cells” (346 occurrences with a total link strength of 2847). Figure 4 shows the bibliometric analysis of keywords in the publications of immunotherapy in CRC showing the co-occurrence of keywords, where the size of nodes indicates the frequency of occurrence.

3.2.2. Citation Analysis for Journals

The journals that received a minimum number of 100 citations were analyzed, and a total of 130 journals met our threshold. New England Journal of Medicine had the highest number of citations (19,449 citations for 14 documents with 924 total link strength), followed by Clinical Cancer Research (7191 citations for 90 documents with 784 total link strength), and Journal of Clinical Oncology (6091 citations for 146 documents with 752 total link strength). Figure 5 depicts bibliometric analysis of the journals in the publications of immunotherapy in CRC, showing journals receiving top citations, where the size of nodes indicates the number of citations received.

3.2.3. Citation Analysis for Institutions

The institutions that had at least 10 publications receiving at least 100 citations were also analyzed, and documents co-authored by authors from more than 25 institutions were excluded. In total, 383 institutions met our thresholds criteria. Johns Hopkins University had the highest number of citations (18,666 citations for 69 documents with 2588 total link strength), followed by Memorial Sloan Kettering Cancer Center (12,025 citations for 93 documents with 1767 total link strength), and Yale University (9858 citations for 17 documents with 718 total link strength). Figure 6 shows the bibliometric analysis of the institutions in the publications of immunotherapy in CRC, showing institutions receiving top citations, where the size of nodes indicates the number of citations received.

3.2.4. Citation Analysis for Countries

The countries that had at least 100 publications receiving at least 1000 citations were analyzed, and documents co-authored by authors from more than 25 countries were excluded. A total of 12 countries met our thresholds criteria. The USA had the highest number of citations (72,060 citations for 1408 documents with 8509 total link strength), followed by France (13,172 citations for 262 documents with 3512 total link strength), and the People’s Republic of China (12,830 citations for 713 documents with 3725 total link strength). Figure 7 demonstrates the bibliometric analysis of the countries in the publications of immunotherapy in CRC showing countries receiving top citations, where the size of nodes indicates the number of citations received.

3.2.5. Co-Authorship Analysis

The authors with at least five publications receiving at least 10 citations were included, and documents co-authored by more than 25 authors were excluded. In total, 394 authors met our criteria. Drew Pardoll had the highest number of citations (4650 citations for eight documents with 30 total link strength), followed by Janis Taube (4394 citations for five documents with 19 total link strength), and Lieping Chen (3779 citations for five documents with 8eighttotal link strength). Figure 8 shows the bibliometric analysis of the authors of publications of immunotherapy in CRC showing authors receiving top citations, where the density indicates the number of citations received.

4. Discussion

Health authorities are increasingly recognizing the role of bibliometrics in evidence-based policy and patient care. In every country, knowledge generation in oncology is a vital phase in the care process. By leading and supporting government cancer control strategies, this can have a substantial impact on patient outcome.
This study aimed to analyze immunotherapy research trends for colon cancer. By using bibliometric analysis of the subject, the status and characteristics of relevant publications were explored, including the most cited articles, research institutions, and journals. The objective was to provide ideas and direction to researchers by identifying current trends in this subject. This bibliometric analysis included every related article from the Web of Science Core Collection database until May 2021, rendering a visual and systematic overview of immunotherapy research trends for colon cancer.
Annual publications on the topic have grown gradually since 2012. A significant increase in the number of articles published took place between 2015 and 2016, reflecting the emergence of checkpoint blockade immunotherapy and the subsequent interest it attracted from the research community [21]. For unresectable or metastatic mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H) CRC, the FDA has approved three immune checkpoint inhibitors (ICIs) targeting PD-1 (pembrolizumab, nivolumab) and CTLA-4 (ipilimumab) in 2017 and 2018, respectively [22,23].
By finding the most common keywords used, we can better understand the direction of academic research and the areas that have been identified as the most promising and deserving of attention. It should come as no surprise that the top keywords found by our analysis are related either to the specific characteristics of the tumor (“expression” and “microsatellite instability”) or to the immune system and its components (“t-cells”/“dendritic cell”). In the study of the effect of immunotherapy in the treatment of CRC, special attention is given to the MSI-H subtype. This type of cancer cell has a high level of microsatellite instability, resulting in a high number of mutations [24]. Such characteristics make it susceptible to checkpoint inhibitors. Although much of the research in this field has concentrated on this variant, there are also attempts to expand the efficacy of immunotherapy to all types of CRC, either by using sensitization to checkpoint inhibition therapy or by using other methods, such as vaccines or CAR-T cell therapy [21].
Adaptive immunotherapy has dominated contemporary cancer immunotherapy research according to an analysis of papers published between 2015 and 2018, regardless of primary tumor site [25]. Subcategory analysis of tumor immunotherapy in the research of adaptive immunity revealed that the most popular subjects were immune checkpoint inhibitors, CAR-T, and cancer vaccines. Dendritic cells were the most studied issues in innate immunity research, possibly because of their capacity to trigger primary immune responses, as well as linking innate and adaptive immunity systems [25]. Using CAR-T cell therapy, the patient’s own T cells are harvested and genetically modified before being reinfused. This approach has shown promise in hematological malignancies [26,27], and it has also been advocated for solid tumors. However, there are no CAR-T cell treatments currently approved for CRC despite several studies that have entered clinical trials as a result of ongoing fundamental research efforts [28].
The USA (n = 1423) and China (n = 702) are the leading countries by the number of publications, accounting for more than half of all immunotherapy-related articles published. The following positions were occupied by Germany, Italy, and Japan (9%, 8%, and 7%, respectively). The 10 most cited papers in the field have all been published by American journals, suggesting that the USA has remained the frontrunner in immunotherapy research in terms of both quantity and quality over the years. The New England Journal of Medicine had the highest number of citations, while Clinical Cancer Research and Journal of Clinical Oncology ranked number two and three, respectively. Institut National De La Sante Et De La Recherche Medicale Inserm had the most published articles (n = 144; 3.621%), followed by the American Universities of Texas System and Harvard (n = 140; 3.520% and n = 119; 2.992%, respectively). Furthermore, among the first 10 institutions by the number of published papers, other French and German centers also appeared. However, when considering the number of citation articles published by an institution received, Johns Hopkins University leads. The Memorial Sloan Kettering Cancer Center and Yale University place second and third.
According to studies, articles must acquire enough citations two to three years following publication for bibliometric measurements to be valid, as citations accumulate gradually over time [29]. The consequence will be a bias in any ranking of the most highly cited articles published across a specific timeframe in favor of older papers, regardless of the field or journal. Individual authors are subject to the same principle—bibliometric indicators benefit senior writers [30].
Researchers can assess the impact of a series of articles by monitoring their citations and categorizing them further by a single author, organization, or an entire country. Higher citation counts imply a greater level of influence. There are a variety of reasons why authors cite other publications. Motives may include reinforcing a point made in the text, naming sources for methods they employ, clarifying a certain technique, or acknowledging mentors or authorities in the area. Occasionally, authors intend to discuss examples of faulty procedures or outcomes that are deceptive. These variations cannot be addressed by current bibliometric criteria, which tally all citations identically regardless of the citation’s real purpose [30].
The amount of citations a publication receives does not indicate if the study described in that paper had a positive impact on people’s health, which is the collective goal for medical research. The only aspect that can be determined is whether or not the paper was helpful to other writers in the process of producing their own articles [30].
To the best of our knowledge, this is the first bibliometric investigation of immunotherapy in colorectal cancer. The vast majority of publications in the subject of immunotherapy in CRC were covered by data obtained from available sources. The data presented might not represent the entire picture of the immunotherapy research in CRC, because conference papers, medical thesis and patents were not included in document screening. Furthermore, bibliometric indicators have a number of limitations, and caution should be used when interpreting the results of the study.
Our study may suffer from the usual shortcomings of bibliometrics. Our citation analysis was based on the search result of the Web of Science Core Collection database, which might mean that significant publications that were available in other databases, such as Google and Scopus, could have been overlooked. Another small number of articles could have been missed by only searching for keywords in the title, abstract, author keywords, and Keywords Plus. Citation analyses have their own inherent problems, such as reliance on the number of times an article has been cited—an aspect that depends on a multitude of uncontrollable factors.

5. Conclusions

The study analyzed global academic publications related to immunotherapy and applied to CRC research quantitatively and qualitatively. There was an increase in the number of publications on the subject worldwide since 2012, and the tendency is toward continued growth in terms of the average volume of published articles. Results also showed the interest the scientific world has for the MSI-H variant of CRC and the way immunotherapy can be used to more effectively treat CRC.

Author Contributions

Conceptualization, D.S., C.L., I.-I.P. and C.V.L.; methodology, D.S., C.L. and C.V.L.; software, D.S., C.V.L. and S.R.V.; validation: C.L., I.-I.P., E.A.M. and M.P.; formal analysis, D.S., C.V.L., C.L. and S.R.V.; investigation, I.-I.P.; resources, D.S. and C.V.L.; data curation, E.A.M. and M.P.; writing—original draft preparation, D.S., C.L., I.-I.P. and C.V.L.; writing—review and editing, D.S., C.L., S.R.V. and C.V.L.; visualization, S.R.V., E.A.M. and M.P.; supervision, D.S. and C.V.L.; project administration, D.S.; funding acquisition, D.S. and C.V.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Acknowledgments

We want to acknowledge the support of the Romanian National Society of Medical Oncology (SNOMR) for the payment of the APC.

Conflicts of Interest

The author Madalina Preda is an employee of MDPI; however, she does not work for the journal Healthcare at the time of submission and publication.

References

  1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
  2. Yoshino, T.; Arnold, D.; Taniguchi, H.; Pentheroudakis, G.; Yamazaki, K.; Xu, R.-H.; Kim, T.W.; Ismail, F.; Tan, I.B.; Yeh, K.-H.; et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann. Oncol. 2018, 29, 44–70. [Google Scholar] [CrossRef] [PubMed]
  3. Ganesh, K.; Stadler, Z.K.; Cercek, A.; Mendelsohn, R.B.; Shia, J.; Segal, N.H.; Diaz, L.A., Jr. Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 361–375. [Google Scholar] [CrossRef]
  4. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372, 2509–2520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Overman, M.J.; McDermott, R.; Leach, J.L.; Lonardi, S.; Lenz, H.-J.; Morse, M.A.; Desai, J.; Hill, A.; Axelson, M.; Moss, R.A.; et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 2017, 18, 1182–1191. [Google Scholar] [CrossRef]
  6. Lipson, E.J.; Sharfman, W.H.; Drake, C.G.; Wollner, I.; Taube, J.M.; Anders, R.A.; Xu, H.; Yao, S.; Pons, A.; Chen, L.; et al. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clin. Cancer Res. 2012, 19, 462–468. [Google Scholar] [CrossRef] [Green Version]
  7. Moed, H.F. New developments in the use of citation analysis in research evaluation. Arch. Immunol. Ther. Exp. 2009, 57, 13–18. [Google Scholar] [CrossRef] [PubMed]
  8. Jin, B.; Wu, X.; Xu, G.; Xing, J.; Wang, Y.; Yang, H.; Du, S.; Mao, Y. Evolutions of the Management of Colorectal Cancer Liver Metastasis: A Bibliometric Analysis. J. Cancer 2021, 12, 3660–3670. [Google Scholar] [CrossRef]
  9. AlRyalat, S.A.S.; Malkawi, L.W.; Momani, S.M. Comparing Bibliometric Analysis Using PubMed, Scopus, and Web of Science Databases. J. Vis. Exp. 2019, 152, e58494. [Google Scholar] [CrossRef]
  10. Van Eck, N.J.; Waltman, L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 2009, 84, 523–538. [Google Scholar] [CrossRef] [Green Version]
  11. Mavligit, G.M.; Gutterman, J.U.; Burgess, M.A.; Khankhanian, N.; Seibert, G.B.; Speer, J.F.; Reed, R.C.; Jubert, A.V.; Martin, R.C.; McBride, C.M.; et al. Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes’ C classification. Preliminary clinical results. Cancer 1975, 36, 2421–2427. [Google Scholar] [CrossRef]
  12. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N. Engl. J. Med. 2012, 366, 2443–2454. [Google Scholar] [CrossRef]
  13. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.M.; Hwu, W.-J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. N. Engl. J. Med. 2012, 366, 2455–2465. [Google Scholar] [CrossRef] [Green Version]
  14. Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28, 3167–3175. [Google Scholar] [CrossRef]
  15. Sato, E.; Olson, S.H.; Ahn, J.; Bundy, B.; Nishikawa, H.; Qian, F.; Kim, T.W.; Ismail, F.; Tan, I.B.; Yeh, K.-H.; et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 18538–18543. [Google Scholar] [CrossRef] [Green Version]
  16. Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A.; et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin. Cancer Res. 2014, 20, 5064–5074. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Pagès, F.; Berger, A.; Camus, M.; Sanchez-Cabo, F.; Coleno-Costes, A.; Molidor, R.; Mlecnik, B.; Kirilovsky, A.; Nilsson, M.; Damotte, D.; et al. Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. N. Engl. J. Med. 2005, 353, 2654–2666. [Google Scholar] [CrossRef]
  18. Binnewies, M.; Roberts, E.W.; Kersten, K.; Chan, V.; Fearon, D.F.; Merad, M.; Coussens, L.M.; Gabrilovich, D.I.; Ostrand-Rosenberg, S.; Hedrick, C.C.; et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018, 24, 541–550. [Google Scholar] [CrossRef] [PubMed]
  19. Chung, C.H.; Mirakhur, B.; Chan, E.; Le, Q.-T.; Berlin, J.; Morse, M.; Murphy, B.A.; Satinover, S.M.; Hosen, J.; Mauro, D.; et al. Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose. N. Engl. J. Med. 2008, 358, 1109–1117. [Google Scholar] [CrossRef] [Green Version]
  20. Goel, S.; Duda, D.G.; Xu, L.; Munn, L.L.; Boucher, Y.; Fukumura, D.; Jain, R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 2011, 91, 1071–1121. [Google Scholar] [CrossRef] [PubMed]
  21. Johdi, N.A.; Sukor, N.F. Colorectal Cancer Immunotherapy: Options and Strategies. Front. Immunol. 2020, 11, 1624. [Google Scholar] [CrossRef]
  22. Marcus, L.; Lemery, S.J.; Keegan, P.; Pazdur, R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin. Cancer Res. 2019, 25, 3753–3758. [Google Scholar] [CrossRef] [Green Version]
  23. Overman, M.J.; Lonardi, S.; Wong, K.Y.M.; Lenz, H.-J.; Gelsomino, F.; Aglietta, M.; Morse, M.A.; Van Cutsem, E.; McDermott, R.; Hill, A.; et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer. J. Clin. Oncol. 2018, 36, 773–779. [Google Scholar] [CrossRef]
  24. Samstein, R.M.; Lee, C.-H.; Shoushtari, A.N.; Hellmann, M.D.; Shen, R.; Janjigian, Y.Y.; Barron, D.A.; Zehir, A.; Jordan, E.J.; Omuro, A.; et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 2019, 51, 202–206. [Google Scholar] [CrossRef]
  25. Lu, K.; Yu, S.; Yu, M.; Sun, D.; Huang, Z.; Xing, H.; Bi, J.; Li, Z.; Li, Z.; Liu, X.; et al. Bibliometric Analysis of Tumor Immunotherapy Studies. Med. Sci. Monit. 2018, 24, 3405–3414. [Google Scholar] [CrossRef] [PubMed]
  26. Neelapu, S.S.; Locke, F.L.; Bartlett, N.L.; Lekakis, L.J.; Miklos, D.B.; Jacobson, C.A.; Braunschweig, I.; Oluwole, O.O.; Siddiqi, T.; Lin, Y.; et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N. Engl. J. Med. 2017, 377, 2531–2544. [Google Scholar] [CrossRef] [PubMed]
  27. Schuster, S.J.; Bishop, M.R.; Tam, C.S.; Waller, E.K.; Borchmann, P.; McGuirk, J.P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.R.; et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2019, 380, 45–56. [Google Scholar] [CrossRef]
  28. Li, H.; Yang, C.; Cheng, H.; Huang, S.; Zheng, Y. CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. J. Cancer 2021, 12, 1804–1814. [Google Scholar] [CrossRef] [PubMed]
  29. Abramo, G.; Cicero, T.; D’Angelo, C.A. Assessing the varying level of impact measurement accuracy as a function of the citation window length. J. Informetr. 2011, 5, 659–667. [Google Scholar] [CrossRef] [Green Version]
  30. Belter, C.W. Bibliometric indicators: Opportunities and limits. J. Med. Libr. Assoc. JMLA 2015, 103, 219–221. [Google Scholar] [CrossRef] [Green Version]
Healthcare 10 00075 g001 550
Figure 1. A PRISMA-like graph detailing the number of retrieved records and the resulted final included number after excluding records.
Figure 1. A PRISMA-like graph detailing the number of retrieved records and the resulted final included number after excluding records.
Healthcare 10 00075 g001
Healthcare 10 00075 g002 550
Figure 2. The number of articles during the last 10 years related to immunotherapy in colorectal cancer according to the Web of Science database.
Figure 2. The number of articles during the last 10 years related to immunotherapy in colorectal cancer according to the Web of Science database.
Healthcare 10 00075 g002
Healthcare 10 00075 g003 550
Figure 3. Top 10 countries regarding the number of publications related to immunotherapy research and colorectal cancer.
Figure 3. Top 10 countries regarding the number of publications related to immunotherapy research and colorectal cancer.
Healthcare 10 00075 g003
Healthcare 10 00075 g004 550
Figure 4. Bibliometric analysis of the keywords in the publications of immunotherapy in CRC showing the co-occurrence of keywords, where the size of nodes indicates the frequency of occurrence.
Figure 4. Bibliometric analysis of the keywords in the publications of immunotherapy in CRC showing the co-occurrence of keywords, where the size of nodes indicates the frequency of occurrence.
Healthcare 10 00075 g004
Healthcare 10 00075 g005 550
Figure 5. Bibliometric analysis of the journals in the publications of immunotherapy in CRC showing journals receiving top citations, where the size of nodes indicates the number of citations received.
Figure 5. Bibliometric analysis of the journals in the publications of immunotherapy in CRC showing journals receiving top citations, where the size of nodes indicates the number of citations received.
Healthcare 10 00075 g005
Healthcare 10 00075 g006 550
Figure 6. Bibliometric analysis of the institutions in the publications of immunotherapy in CRC showing institutions receiving top citations, where the size of nodes indicates the number of citations received.
Figure 6. Bibliometric analysis of the institutions in the publications of immunotherapy in CRC showing institutions receiving top citations, where the size of nodes indicates the number of citations received.
Healthcare 10 00075 g006
Healthcare 10 00075 g007 550
Figure 7. Bibliometric analysis of the countries in the publications of immunotherapy in CRC showing countries receiving top citations, where the size of nodes indicates the number of citations received.
Figure 7. Bibliometric analysis of the countries in the publications of immunotherapy in CRC showing countries receiving top citations, where the size of nodes indicates the number of citations received.
Healthcare 10 00075 g007
Healthcare 10 00075 g008 550
Figure 8. Bibliometric analysis of the authors of publications of immunotherapy in CRC showing authors receiving top citations, where the density indicates the number of citations received.
Figure 8. Bibliometric analysis of the authors of publications of immunotherapy in CRC showing authors receiving top citations, where the density indicates the number of citations received.
Healthcare 10 00075 g008
Table
Table 1. Top 10 institutions in the field immunotherapy research related to colorectal cancer.
Table 1. Top 10 institutions in the field immunotherapy research related to colorectal cancer.
InstitutionNumber of ArticlesPercentage of the Total
Institut National De La Sante Et De La Recherche Medicale Inserm1443.621%
University of Texas System1403.520%
Harvard University1192.992%
Utmd Anderson Cancer Center1132.841%
Assistance Publique Hopitaux Paris Aphp1082.716%
Sorbonne Universite1032.590%
Memorial Sloan Kettering Cancer Center1002.514%
Unicancer972.439%
Helmholtz Association952.389%
Johns Hopkins University942.364%
National Institutes Of Health Nih Usa912.288%
German Cancer Research Center Dkfz862.162%
Table
Table 2. Top 10 journals regarding the number of papers published related to immunotherapy in colorectal cancer according to the Web of Science database.
Table 2. Top 10 journals regarding the number of papers published related to immunotherapy in colorectal cancer according to the Web of Science database.
JournalImpact FactorPublisherNumber of PublicationsPercentage
Journal of Clinical Oncology32.96Amer. Soc. Clinical Oncology1463.671%
Cancer Immunology Immunotherapy5.44Springer1172.942%
Oncoimmunology5.87Landes Bioscience952.389%
Cancer Research9.73Amer. Assoc. Cancer Research912.288%
Clinical Cancer Research10.11Amer. Assoc. Cancer Research902.263%
Cancers6.13Mdpi731.836%
Annals of Oncology18.27Oxford Univ. Press721.810%
Journal For Immunotherapy of Cancer10.25BMC671.685%
International Journal of Cancer5.15Wiley621.559%
Frontiers In Immunology5.09Frontiers Media SA601.509%
Table
Table 3. Top 10 highly cited papers related to immunotherapy in colorectal cancer according to the Web of Science database.
Table 3. Top 10 highly cited papers related to immunotherapy in colorectal cancer according to the Web of Science database.
RankTitleCitation CountJournalDocument TypePublisherOpen AccessYear Published
1Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer [12]7724New England Journal of MedicineArticleMassachusetts Medical Soc.Yes2012
2Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [13]4924New England Journal of MedicineArticleMassachusetts Medical Soc.Yes2012
3PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [4]4454New England Journal of MedicineArticleMassachusetts Medical Soc.Yes2015
4Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [14] 1934Journal of Clinical OncologyArticleAmer. Soc. Clinical OncologyYes2010
5Intraepithelial CD8(+) Tumor-Infiltrating Lymphocytes and A High CD8(+)/Regulatory T Cell Ratio Are Associated with Favorable Prognosis in Ovarian Cancer [15]1560Proceedings of the National Academy of Sciences of The United States of AmericaArticleNatl. Acad. SciencesYes2005
6Association Of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy [16]1472Clinical Cancer ResearchArticleAmer. Assoc. Cancer ResearchYes2014
7Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer [17]1418New England Journal of MedicineArticleMassachusetts Medical Soc.Yes2005
8Understanding The Tumor Immune Microenvironment (TIME) for Effective Therapy [18]950Nature MedicineReviewNature Publishing GroupYes2018
9Cetuximab-Induced Anaphylaxis and Ige Specific for Galactose-Alpha-1,3-Galactose [19]892New England Journal of MedicineArticleMassachusetts Medical Soc.Yes2008
10Normalization of the Vasculature for Treatment of Cancer and Other Diseases [20]897Physiological ReviewsReviewAmer. Physiological Soc.Yes2011
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Sur, D.; Lungulescu, C.; Puscariu, I.-I.; Volovat, S.R.; Preda, M.; Mateianu, E.A.; Lungulescu, C.V. Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. Healthcare 2022, 10, 75. https://doi.org/10.3390/healthcare10010075

AMA Style

Sur D, Lungulescu C, Puscariu I-I, Volovat SR, Preda M, Mateianu EA, Lungulescu CV. Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis. Healthcare. 2022; 10(1):75. https://doi.org/10.3390/healthcare10010075

Chicago/Turabian Style

Sur, Daniel, Cristina Lungulescu, Irina-Ioana Puscariu, Simona Ruxandra Volovat, Madalina Preda, Elena Adriana Mateianu, and Cristian Virgil Lungulescu. 2022. "Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis" Healthcare 10, no. 1: 75. https://doi.org/10.3390/healthcare10010075

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop